- Home
- BVC vs TSHA Comparison
BVC vs TSHA Comparison
Compare BVC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVC | TSHA |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BVC | TSHA |
|---|---|---|
| Price | $10.25 | $6.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.11 |
| AVG Volume (30 Days) | 2.5K | ★ 3.0M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,228.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $0.99 | $1.22 |
| 52 Week High | $15.00 | $6.04 |
Technical Indicators
Market Signals| Indicator | BVC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 76.95 |
| Support Level | $8.05 | $4.39 |
| Resistance Level | $11.62 | N/A |
| Average True Range (ATR) | 0.55 | 0.36 |
| MACD | 0.00 | 0.22 |
| Stochastic Oscillator | 65.81 | 98.98 |
Price Performance
Historical ComparisonAbout BVC BitVentures Limited American Depositary Shares
BitVentures Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. The Company is developing technology businesses in verticals including e-commerce, digital assets, consumer healthcare, and other areas of consumer.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.